Anika Therapeutics, Inc.
ANIK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | 0.54 | 0.14 | 0.11 |
| FCF Yield | 3.69% | -1.09% | -1.37% | 0.11% |
| EV / EBITDA | -30.86 | -50.06 | -69.45 | 142.73 |
| Quality | ||||
| ROIC | -2.69% | -2.80% | -2.48% | -1,131.21% |
| Gross Margin | 56.02% | 50.90% | 56.10% | 73.74% |
| Cash Conversion Ratio | -2.95 | 0.05 | 0.03 | -0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | -20.87% | -17.25% | -15.69% | -11.39% |
| Free Cash Flow Growth | 400.91% | 43.94% | -1,174.18% | -92.76% |
| Safety | ||||
| Net Debt / EBITDA | 10.89 | 11.43 | 10.38 | -20.16 |
| Interest Coverage | -2.67 | 0.00 | -10.32 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.75 | 0.82 | 0.54 | 0.54 |
| Cash Conversion Cycle | 156.77 | 155.33 | 201.44 | 196.60 |